Charles River Laboratories International, Inc. closed at $281.66 on September 18, 2026, a gain of 3.02% for the session. The move extended the stock's seven-day advance to 3.21%, suggesting some near-term buying momentum in the contract research organization's shares.
Despite the recent gains, CRL remains in negative territory on a longer timeframe, with the stock down 3.19% over the past 30 days. That monthly decline points to ongoing headwinds that have weighed on the shares even as Friday's session offered relief.
The company's market capitalization stood at $13.05 billion as of the close. Charles River Laboratories provides drug discovery and development services to pharmaceutical, biotechnology, and government clients worldwide.
